Outcomes of Treatment and Factors Influencing Prognosis in Ugandan Children with Acute Myeloid Leukaemia

• by Richard Nyeko, Mariana Kruger, Nixon Niyonzima, Barnabas Atwiine, Jennifer Zungu, Joyce Balagadde Kambugu, Stijn Verhulst, Jaques van Heerden

• December 18, 2025

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

• July 1, 2026

• 1 min

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

• July 1, 2026

• 1 min

The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment

• by Aliki Vasilakou, Séverine Loizon, Maxime Dubois, Paôline Laurent, Vanja Sisirak, Dorothée Duluc

• July 2, 2026